A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...

October 4, 2012 — The burden of brain amyloid in nondemented elderly persons is lower among those who carry a newly identified gene for late-onset Alzheimer's disease (AD) compared with noncarriers, ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Disrupted sleep patterns in Alzheimer’s disease may be more than a symptom—they could be a driving force. Researchers at ...

The experimental pill ALZ-801 slowed memory decline by 50% and reduced brain shrinkage in early Alzheimer's patients with ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Alzheimer’s disease not only damages memory but also distorts the brain’s internal clock, disrupting the daily rhythms of hundreds of genes tied to brain health.

Could disrupting your internal clock be the key to treating Alzheimer’s? A surprising new study, published in the journal ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Lowering the transcription factor PU.1 reprograms microglia into a neuroprotective, lymphoid-like state that compacts amyloid ...

Shares of Intellia Therapeutics (NTLA) crashed ~28% in the premarket on Friday after the company disclosed that a patient who ...